Structural Analysis of the Colony-Stimulating Factor 3 Gene of Granulocyte Colony-Stimulating Factor-Producing Urothelial Cancer

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Sep 25

PMID 37746465

Authors

Yumiko Okuno

Mai Hori

Mami Hattori-Kato

Hiroshi Fukuhara

Akira Nomiya

Koji Mikami

Takumi Takeuchi

Affiliations

Soon will be listed here.

Abstract

Background Granulocyte colony-stimulating factor (G-CSF) is a member of the CSF family of glycoproteins that regulate the proliferation, differentiation, and mobilization of neutrophils. G-CSF-producing malignant cancers have been reported to occur in various organs and are mostly associated with poor clinical prognosis. Here, we analyzed the structure of the gene encoding the G-CSF protein to delineate the mechanism of G-CSF production by the cancer cells. Methodology Two cases of G-CSF-producing urothelial cancers and three cases of G-CSF-nonproducing bladder cancers were enrolled for genetic analysis. Results In one case of G-CSF-producing bladder cancer, six somatic mutations were detected in the 5'- upstream region of the gene. No somatic mutations in the gene were detected in another case of G-CSF-producing renal pelvic cancer and G-CSF-nonproducing bladder cancers. Copy numbers of the gene were not increased in G-CSF-producing urothelial cancers. Conclusions Somatic mutations in the 5'- upstream region of the gene may cause G-CSF protein overproduction.

References

Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T . GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017; 2017. PMC: 5467550. DOI: 10.1093/database/bax028. View

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

Elliott D, Perner J, Li X, Symmons M, Verstak B, Eldridge M . Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis. PLoS Genet. 2017; 13(5):e1006808. PMC: 5460900. DOI: 10.1371/journal.pgen.1006808. View

ONeill L, Bowie A . The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007; 7(5):353-64. DOI: 10.1038/nri2079. View

Schilling J, Martin S, Hung C, Lorenz R, Hultgren S . Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli. Proc Natl Acad Sci U S A. 2003; 100(7):4203-8. PMC: 153071. DOI: 10.1073/pnas.0736473100. View

Muramatsu-Maekawa Y, Taniguchi T, Ito H, Nakane K, Kato T, Tsuchiya T . Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review. J Immunother. 2020; 43(4):134-138. DOI: 10.1097/CJI.0000000000000311. View

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

Nagata H, Komatsu S, Takaki W, Okayama T, Sawabe Y, Ishii M . Granulocyte colony-stimulating factor-producing hepatocellular carcinoma with abrupt changes. World J Clin Oncol. 2016; 7(5):380-386. PMC: 5056329. DOI: 10.5306/wjco.v7.i5.380. View

Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K . Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001; 92(9):2399-405. DOI: 10.1002/1097-0142(20011101)92:9<2399::aid-cncr1588>3.0.co;2-w. View

10.

Tsuchiya M, Asano S, Kaziro Y, Nagata S . Isolation and characterization of the cDNA for murine granulocyte colony-stimulating factor. Proc Natl Acad Sci U S A. 1986; 83(20):7633-7. PMC: 386775. DOI: 10.1073/pnas.83.20.7633. View

11.

Powles T, Eder J, Fine G, Braiteh F, Loriot Y, Cruz C . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. DOI: 10.1038/nature13904. View

12.

Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O . Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature. 1986; 319(6052):415-8. DOI: 10.1038/319415a0. View

13.

Miyazaki K, Shiba A, Ikeda T, Higashi Y, Aga M, Hamakawa Y . Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study. BMC Cancer. 2022; 22(1):977. PMC: 9469597. DOI: 10.1186/s12885-022-10065-w. View

14.

Nagata S, Tsuchiya M, Asano S, Yamamoto O, Hirata Y, Kubota N . The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor. EMBO J. 1986; 5(3):575-81. PMC: 1166801. DOI: 10.1002/j.1460-2075.1986.tb04249.x. View

15.

Morris K, Khan H, Ahmad A, Weston L, Nofchissey R, Pinchuk I . G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. Br J Cancer. 2014; 110(5):1211-20. PMC: 3950854. DOI: 10.1038/bjc.2013.822. View

16.

Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L . Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11):1015-1026. PMC: 5635424. DOI: 10.1056/NEJMoa1613683. View

17.

Nishizawa M, Tsuchiya M, Nagata S . Multiple elements in the promoter of granulocyte colony-stimulating factor gene regulate its constitutive expression in human carcinoma cells. J Biol Chem. 1990; 265(10):5897-902. View

18.

Manz M, Boettcher S . Emergency granulopoiesis. Nat Rev Immunol. 2014; 14(5):302-14. DOI: 10.1038/nri3660. View

19.

Anger B, Bockman R, Andreeff M, Erlandson R, Jhanwar S, Kameya T . Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma. Cancer. 1982; 50(8):1518-29. DOI: 10.1002/1097-0142(19821015)50:8<1518::aid-cncr2820500812>3.0.co;2-r. View